<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244490</url>
  </required_header>
  <id_info>
    <org_study_id>SPD503-316</org_study_id>
    <secondary_id>2010-018579-12</secondary_id>
    <nct_id>NCT01244490</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For children and adolescents, how does SPD503 compare to placebo for the treatment of
      Attention-Deficit/Hyperactivity Disorder (ADHD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF)</measure>
    <time_frame>Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores</measure>
    <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF</measure>
    <time_frame>Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The WFIRS-P Learning in School Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF</measure>
    <time_frame>Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The WFIRS-P Family Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Severity of Illness (CGI-S) - LOCF</measure>
    <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF</measure>
    <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF</measure>
    <time_frame>Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The WFIRS-P Global Score is the mean of 50 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF</measure>
    <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The WFIRS-P Academic Performance Domain is the mean of 4 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF</measure>
    <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The WFIRS-P Behavior in School Domain is the mean of 6 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF</measure>
    <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The WFIRS-P Life Skills Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF</measure>
    <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The WFIRS-P Child Self-Concept Domain is the mean of 3 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF</measure>
    <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The WFIRS-P Social Domain is the mean of 7 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF</measure>
    <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The WFIRS-P Risk Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF</measure>
    <time_frame>Baseline and up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
    <description>The BPRS-C characterizes childhood behavioral and emotional symptomatology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structure Side-Effect Questionnaire</measure>
    <time_frame>Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years</time_frame>
    <description>The Structured Side-effect Questionnaire is a simple checklist of 17 side effects. The subject indicates whether a side effect has occurred since the last visit by marking 'yes' on the checklist for each of the events listed. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years</time_frame>
    <description>C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">338</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Extended-release Guanfacine Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine Hydrochloride</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active Reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended-release Guanfacine Hydrochloride</intervention_name>
    <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.</description>
    <arm_group_label>Extended-release Guanfacine Hydrochloride</arm_group_label>
    <other_name>Intuniv</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine Hydrochloride</intervention_name>
    <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose</description>
    <arm_group_label>Atomoxetine Hydrochloride</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, aged 6 17 years at the time of consent/assent at Screening (Visit 1).

          2. Subject's parent or legally authorised representative (LAR) must provide signature of
             informed consent, and there must be documentation of assent (if applicable) by the
             subject indicating that the subject is aware of the investigational nature of the
             study and the required procedures and restrictions in accordance with the
             International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidance
             E6, and applicable regulations before completing any study related procedures at
             Screening (Visit 1).

          3. Subject meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text
             Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD, combined sub-type,
             hyperactive/impulsive sub-type, or inattentive sub-type based on a detailed
             psychiatric evaluation using the Kiddie Schedule for Affective Disorders and
             Schizophrenia - Present and Lifetime version (K-SADS-PL).

          4. Subject has a minimum ADHD-RS-IV total score of 32 at Baseline (Visit 2).

          5. Subject has a minimum CGI-S score of 4 at Baseline (Visit 2).

          6. Subject is functioning at an age-appropriate level intellectually, as judged by the
             Investigator.

          7. Subject and parent/LAR understand, are willing, able, and likely to fully comply with
             the study procedures and restrictions defined in this protocol.

          8. Subject is able to swallow intact tablets and capsules.

          9. Subject who is a female of child-bearing potential (FOCP), defined as greater than or
             equal to 9 years of age or &lt;9 years of age and is menarchal, must have a negative
             serum beta Human Chorionic Gonadotropin (hCG) pregnancy test at Screening (Visit 1)
             and a negative urine pregnancy test at Baseline (Visit 2) and agree to comply with any
             applicable contraceptive requirements of the protocol.

         10. Subject has supine and standing blood pressure (BP) measurement within the 95th
             percentile for age, sex, and height

        Exclusion Criteria:

          1. Subject has a current, controlled (requiring a prohibited medication or behavioural
             modification program) or uncontrolled, co-morbid psychiatric diagnosis [except
             oppositional defiant disorder (ODD)], including any severe co-morbid Axis II disorders
             or severe Axis I disorders such as post traumatic stress disorder (PTSD), bipolar
             illness, psychosis, pervasive developmental disorder, obsessive-compulsive disorder
             (OCD), substance abuse disorder, or other symptomatic manifestations or lifetime
             history of bipolar illness, psychosis or conduct disorder that, in the opinion of the
             Investigator, contraindicate treatment with SPD503 or STRATTERA or confound efficacy
             or safety assessments.

          2. Subject is well-controlled on their current medication, with acceptable tolerability,
             and the parent/caregiver does not object to the current medication.

          3. Subject has any condition or illness including a clinically significant abnormal
             Screening (Visit 1) laboratory values which, in the opinion of the Investigator,
             represents an inappropriate risk to the subject and/or could confound the
             interpretation of the study. Mild stable asthma treated without the use of beta-2
             agonist is not exclusionary.

          4. Subject has a known history or presence of structural cardiac abnormalities,
             cardiovascular or cerebrovascular disease, serious heart rhythm abnormalities,
             syncope, tachycardia, cardiac conduction problems (eg, clinically significant heart
             block or QT interval prolongation), exercise-related cardiac events including syncope
             and pre syncope, or clinically significant bradycardia.

          5. Subject has a known family history of sudden cardiac death, ventricular arrhythmia, or
             QT prolongation.

          6. Subjects with orthostatic hypotension or a known history of hypertension.

          7. Subject has glaucoma.

          8. Subject has clinically significant ECG findings as judged by the Investigator with
             consideration of the central ECG laboratory's interpretation.

          9. Subject has a history of a seizure disorder (other than a single childhood febrile
             seizure occurring before the age of 3 years) or the presence of a serious tic disorder
             including Tourette's Syndrome.

         10. Current use of any prohibited medication or other medications, including monoamine
             oxidase inhibitors, herbal supplements, that affect BP or heart rate potent CYP2D6
             inhibitors, medications known to prolong the QT/QTc interval, medications that lower
             seizure threshold, pressor agents, beta-2 agonists, medications that affect
             noradrenaline, medications that have central nervous system (CNS) effects or affect
             cognitive performance, such as sedating antihistamines and decongestant
             sympathomimetics (inhaled bronchodilators are permitted) or a history of chronic use
             of sedating medications [ie, antihistamines]) in violation of the protocol specified
             washout criteria at Baseline (Visit 2).

         11. Subject has a history of alcohol or other substance abuse or dependence, as defined by
             DSM-IV (with the exception of nicotine) within the last 6 months.

         12. Subject has taken another investigational product within 30 days prior to Baseline
             (Visit 2).

         13. Subject is significantly overweight based on Center for Disease Control and Prevention
             Body Mass Index (BMI)-for-age gender specific charts at the Screening (Visit 1).
             Significantly overweight is defined as a BMI &gt;95th percentile.

         14. Children aged 6 12 years with a body weight of less than 25kg or adolescents aged 13
             17 years with a body weight of less than 34kg or greater than 91kg at Screening (Visit
             1).

         15. Subject has a known or suspected allergy, hypersensitivity, or clinically significant
             intolerance to guanfacine hydrochloride or atomoxetine hydrochloride, or any
             components found in SPD503 or STRATTERA.

         16. Clinically important abnormality on drug and alcohol screen (excluding the subject's
             current ADHD stimulant if applicable) at Screening (Visit 1)

         17. Subject is female and is pregnant or currently lactating.

         18. Subject failed screening or was previously enrolled in this study.

         19. Subject is currently considered a suicide risk in the opinion of the Investigator, has
             previously made a suicide attempt, or has a prior history of, or is currently
             demonstrating active suicide ideation. Subjects with intermittent passive suicidal
             ideation are not necessarily excluded based on the assessment of the Investigator.

         20. History of failure to respond to an adequate trial of an α2-agonist or atomoxetine
             hydrochloride for the treatment of ADHD (consisting of an appropriate dose and
             adequate duration of therapy in the opinion of the investigator).

         21. Subjects with renal or hepatic insufficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Psychiatric Centers at San Diego, Feighner Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Center for Behavioral Medicine</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center, Dept. of Psychiatry</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovis Health</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claghorn-Lesem Research Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R/D Clincial Research, Inc.</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroScience Inc.</name>
      <address>
        <city>Herndon</city>
        <state>Virginia</state>
        <zip>20170</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Graz-Universitaklinik fur Kinder-und Jugendheilkunde</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut für Psychosomatik</name>
      <address>
        <city>Wien</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Grazyna B. Jackiewicz, MD</name>
      <address>
        <city>Niagra Falls</city>
        <state>Ontario</state>
        <zip>L2E 6A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JPM Van Stralen Medicine Professional Corp.</name>
      <address>
        <city>Ottowa</city>
        <state>Ontario</state>
        <zip>K2G 1W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre HospitalierUniversitaire d'Amiens, Hoptial Nord</name>
      <address>
        <city>Amiens Cedex</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Charles Perens - Service de Psychiatrie de l'Enfant et de l'Adolescent</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier des Pyrenees</name>
      <address>
        <city>Chartres</city>
        <zip>28018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Wolff</name>
      <address>
        <city>Hagen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58093</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Andreas Mahler</name>
      <address>
        <city>Achim</city>
        <zip>28832</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft Drs. Willem Geraets/Gabriele Lucassen</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40215</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Walter Robert Otto</name>
      <address>
        <city>Fulda</city>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Friedrich Kaiser un Ingrid Marinesse</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut fur Ganzheitiche Medzin und Wissenschaft GmbH</name>
      <address>
        <city>Huttenberg</city>
        <zip>35625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes-Guttenberg-Universitat Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut fur Seelische Geseundheit Mannheim Klinik for Psuchiatrie und Psychotherapie des Kindes</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somni Bene GmbH - Institut für Medizinische Forschung und Schlafmedizin</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Child and Adolescent Psychiatry</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Stella Maris - U.O. Psichiatria e Psicofarmacologia Eta' Evolutiva</name>
      <address>
        <city>Pisa</city>
        <zip>56018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico G.B.Rossi - Azienda Ospedaliera Universitaria Integrata Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Neuropsychiatrii Neuromed</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>54-235</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Borys Gniot</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Dzieciecy Szpital Kliniczny</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-576</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych PI-House Sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-546</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Gdan Skie Centrum Zdrowia</name>
      <address>
        <city>Gdansk</city>
        <zip>80-542</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Psychiatrii Doroslych, Dzieci i Mlodziezy, Miroslaw Dabkowski</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta Pentru Copii Cluj</name>
      <address>
        <city>Cluj Napoca</city>
        <state>Cluj</state>
        <zip>400660</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii &quot;Louis Turcanu&quot;</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300239</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alexandru Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Socola</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlínica Guipuzkoa</name>
      <address>
        <city>Donostia-San Sebastián</city>
        <zip>20009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marítimo, (USMI-J)</name>
      <address>
        <city>Malaga</city>
        <zip>29620</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Dia Infantil y Juvenil Dr Diego Guigou y Costa</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Neurología Pediatrica</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barnsjukhus</name>
      <address>
        <city>Goteborg</city>
        <zip>411 18</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barn och Ungdomsmedicin klinik Mölnlycke</name>
      <address>
        <city>Mölnlycke</city>
        <zip>43530</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BUP mottagningen Varberg</name>
      <address>
        <city>Varberg</city>
        <zip>432 43</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology, Psychiatry and Narcology of the AMS of Ukraine</name>
      <address>
        <city>Kharkov</city>
        <state>Kharkiv</state>
        <zip>61068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Psychiatric Hospital</name>
      <address>
        <city>Donetsk</city>
        <zip>83037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Institution &quot;Institute of healthcare for children and adolescences NAMNU</name>
      <address>
        <city>Kharkiv</city>
        <zip>61153</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kherson Regional Psychiatric Hospital</name>
      <address>
        <city>Kherson</city>
        <zip>73488</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lviv Regional Clinical Psychiatric Hospital</name>
      <address>
        <city>Lviv</city>
        <zip>79021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odesa Regional Psychoneurological Dispensary, Outpatient Dept</name>
      <address>
        <city>Odesa</city>
        <zip>65084</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O.F. Maltsev Poltava Regional Psychiatric Hospital</name>
      <address>
        <city>Poltava</city>
        <zip>36000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia National Medical University - Vinnytsia Regional Psycho-Neurological Hospital</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital</name>
      <address>
        <city>Kirkcaldy</city>
        <state>Fife</state>
        <zip>KY2 5AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget University Hospital NHS Trust</name>
      <address>
        <city>Great Yarmouth</city>
        <state>Norfolk</state>
        <zip>NR31 6SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ashurt Child and Family Centre</name>
      <address>
        <city>Ashurst</city>
        <state>Southampton</state>
        <zip>SO40 7AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horsham Child and Adolescent Mental Health Services</name>
      <address>
        <city>Horsham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5 Boroughs Partnership NHS Trust</name>
      <address>
        <city>Wigan</city>
        <zip>WN2 2JA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014 Dec;24(12):1861-72. doi: 10.1016/j.euroneuro.2014.09.014. Epub 2014 Oct 23.</citation>
    <PMID>25453486</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2010</study_first_submitted>
  <study_first_submitted_qc>November 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <results_first_submitted>May 9, 2014</results_first_submitted>
  <results_first_submitted_qc>June 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 14, 2014</results_first_posted>
  <last_update_submitted>February 4, 2015</last_update_submitted>
  <last_update_submitted_qc>February 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Once daily</description>
        </group>
        <group group_id="P2">
          <title>Guanfacine Hydrochloride</title>
          <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
        </group>
        <group group_id="P3">
          <title>Atomoxetine Hydrochloride</title>
          <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="89"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population defined as all randomized subjects who took at least 1 dose of investigational product. One subject did not receive investigational product, therefore n = 337.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Once daily</description>
        </group>
        <group group_id="B2">
          <title>Guanfacine Hydrochloride</title>
          <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
        </group>
        <group group_id="B3">
          <title>Atomoxetine Hydrochloride</title>
          <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="112"/>
            <count group_id="B4" value="337"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.0" spread="2.76"/>
                    <measurement group_id="B2" value="10.9" spread="2.77"/>
                    <measurement group_id="B3" value="10.5" spread="2.81"/>
                    <measurement group_id="B4" value="10.8" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6-12 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13-17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>AUSTRIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CANADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRANCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GERMANY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IRELAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITALY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROMANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWEDEN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKRAINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED KINGDOM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF)</title>
        <description>The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomized subjects who took at least 1 dose of investigational product. If more than 20% of the items used for summing a score were missing, the score was set to missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF)</title>
          <description>The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set (FAS) defined as all randomized subjects who took at least 1 dose of investigational product. If more than 20% of the items used for summing a score were missing, the score was set to missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0" spread="1.1612"/>
                    <measurement group_id="O2" value="-23.9" spread="1.1531"/>
                    <measurement group_id="O3" value="-18.8" spread="1.1549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-8.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.9</ci_lower_limit>
            <ci_upper_limit>-5.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores</title>
        <description>Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. Not all subjects in the FAS population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores</title>
          <description>Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. Not all subjects in the FAS population had data for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1"/>
                    <measurement group_id="O2" value="67.9"/>
                    <measurement group_id="O3" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Percentage Improvement</param_type>
            <param_value>23.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.1</ci_lower_limit>
            <ci_upper_limit>36.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Percentage Improvement</param_type>
            <param_value>12.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>25.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF</title>
        <description>The WFIRS-P Learning in School Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Learning and School Domain Scores at Week 10/13 - LOCF</title>
          <description>The WFIRS-P Learning in School Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.419" spread="0.0537"/>
                    <measurement group_id="O2" value="-0.636" spread="0.0527"/>
                    <measurement group_id="O3" value="-0.581" spread="0.0534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.217</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.358</ci_lower_limit>
            <ci_upper_limit>-0.076</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.162</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.305</ci_lower_limit>
            <ci_upper_limit>-0.019</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF</title>
        <description>The WFIRS-P Family Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the WFIRS-P Family Domain Score at Week 10/13 - LOCF</title>
          <description>The WFIRS-P Family Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.409" spread="0.0568"/>
                    <measurement group_id="O2" value="-0.617" spread="0.0558"/>
                    <measurement group_id="O3" value="-0.499" spread="0.0566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.209</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.358</ci_lower_limit>
            <ci_upper_limit>-0.059</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.242</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.090</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.241</ci_lower_limit>
            <ci_upper_limit>0.061</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression-Severity of Illness (CGI-S) - LOCF</title>
        <description>CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. Not all subjects in the FAS population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression-Severity of Illness (CGI-S) - LOCF</title>
          <description>CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. Not all subjects in the FAS population had data for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 (Normal, not at all ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (Borderline mentally ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="23.2"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (Mildly ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 (Moderately ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="22.3"/>
                    <measurement group_id="O3" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 (Markedly ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2"/>
                    <measurement group_id="O2" value="5.4"/>
                    <measurement group_id="O3" value="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 (Severely ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3"/>
                    <measurement group_id="O2" value="3.6"/>
                    <measurement group_id="O3" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 (Amongst the most extremely ill)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.196</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF</title>
        <description>HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. Not all subjects in the FAS population had data for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Health Utilities Index-2/3 (HUI 2/3) Scores - LOCF</title>
          <description>HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. Not all subjects in the FAS population had data for this outcome.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.927" spread="0.0950"/>
                    <measurement group_id="O2" value="0.922" spread="0.0908"/>
                    <measurement group_id="O3" value="0.913" spread="0.1052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF</title>
        <description>The WFIRS-P Global Score is the mean of 50 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Baseline and Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the WFIRS-P Global Score at Week 10/13 - LOCF</title>
          <description>The WFIRS-P Global Score is the mean of 50 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.321" spread="0.0387"/>
                    <measurement group_id="O2" value="-0.487" spread="0.0374"/>
                    <measurement group_id="O3" value="-0.425" spread="0.0384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.165</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.266</ci_lower_limit>
            <ci_upper_limit>-0.064</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.048</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.104</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.207</ci_lower_limit>
            <ci_upper_limit>-0.001</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF</title>
        <description>The WFIRS-P Academic Performance Domain is the mean of 4 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the WFIRS-P Academic Performance Domain Score at Week 10/13 - LOCF</title>
          <description>The WFIRS-P Academic Performance Domain is the mean of 4 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.555" spread="0.0784"/>
                    <measurement group_id="O2" value="-0.766" spread="0.0757"/>
                    <measurement group_id="O3" value="-0.681" spread="0.0759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.211</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.416</ci_lower_limit>
            <ci_upper_limit>-0.007</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.231</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.125</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.331</ci_lower_limit>
            <ci_upper_limit>0.080</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF</title>
        <description>The WFIRS-P Behavior in School Domain is the mean of 6 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the WFIRS-P Behavior in School Domain Score at Week 10/13 - LOCF</title>
          <description>The WFIRS-P Behavior in School Domain is the mean of 6 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.363" spread="0.0512"/>
                    <measurement group_id="O2" value="-0.592" spread="0.0502"/>
                    <measurement group_id="O3" value="-0.544" spread="0.0509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Diiference in Least Squares Mean</param_type>
            <param_value>-0.229</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.364</ci_lower_limit>
            <ci_upper_limit>-0.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.181</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.317</ci_lower_limit>
            <ci_upper_limit>-0.045</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF</title>
        <description>The WFIRS-P Life Skills Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the WFIRS-P Life Skills Domain Score at Week 10/13 - LOCF</title>
          <description>The WFIRS-P Life Skills Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.383" spread="0.0422"/>
                    <measurement group_id="O2" value="-0.477" spread="0.0411"/>
                    <measurement group_id="O3" value="-0.450" spread="0.0422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.094</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.204</ci_lower_limit>
            <ci_upper_limit>0.017</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.242</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.067</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.180</ci_lower_limit>
            <ci_upper_limit>0.046</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF</title>
        <description>The WFIRS-P Child Self-Concept Domain is the mean of 3 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the WFIRS-P Child Self-Concept Domain Score at Week 10/13 - LOCF</title>
          <description>The WFIRS-P Child Self-Concept Domain is the mean of 3 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.312" spread="0.0544"/>
                    <measurement group_id="O2" value="-0.361" spread="0.0528"/>
                    <measurement group_id="O3" value="-0.390" spread="0.0536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.500</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.191</ci_lower_limit>
            <ci_upper_limit>0.094</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.288</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.222</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF</title>
        <description>The WFIRS-P Social Domain is the mean of 7 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the WFIRS-P Social Domain Score at Week 10/13 - LOCF</title>
          <description>The WFIRS-P Social Domain is the mean of 7 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.322" spread="0.0537"/>
                    <measurement group_id="O2" value="-0.555" spread="0.0519"/>
                    <measurement group_id="O3" value="-0.434" spread="0.0532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.233</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.374</ci_lower_limit>
            <ci_upper_limit>-0.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.124</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.111</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.253</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF</title>
        <description>The WFIRS-P Risk Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the WFIRS-P Risk Domain Score at Week 10/13 - LOCF</title>
          <description>The WFIRS-P Risk Domain is the mean of 10 items, ranging from 0 (never/not at all) to 3 (very often/very much). Higher scores indicate greater functional impairment. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Full Analysis Set. If more than 30% of items used to derive the score were missing, the corresponding score was considered as missing.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.134" spread="0.0284"/>
                    <measurement group_id="O2" value="-0.190" spread="0.0275"/>
                    <measurement group_id="O3" value="-0.173" spread="0.0285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.139</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.056</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.131</ci_lower_limit>
            <ci_upper_limit>0.018</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.315</p_value>
            <p_value_desc>Nominal p-value uncorrected for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.039</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.115</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF</title>
        <description>The BPRS-C characterizes childhood behavioral and emotional symptomatology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
        <time_frame>Baseline and up to 10 weeks for children aged 6-12 years and up to 13 weeks for adolescents aged 13-17 years</time_frame>
        <population>Safety Population defined as of randomized subjects who took at least 1 dose of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Weeks 10/13 - LOCF</title>
          <description>The BPRS-C characterizes childhood behavioral and emotional symptomatology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology. Outcome measure is at 10 weeks for ages 6-12 years and at 13 weeks for ages 13-17 years.</description>
          <population>Safety Population defined as of randomized subjects who took at least 1 dose of investigational product.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="8.82"/>
                    <measurement group_id="O2" value="-8.3" spread="8.40"/>
                    <measurement group_id="O3" value="-6.5" spread="9.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Structure Side-Effect Questionnaire</title>
        <description>The Structured Side-effect Questionnaire is a simple checklist of 17 side effects. The subject indicates whether a side effect has occurred since the last visit by marking ‘yes’ on the checklist for each of the events listed. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.</description>
        <time_frame>Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Structure Side-Effect Questionnaire</title>
          <description>The Structured Side-effect Questionnaire is a simple checklist of 17 side effects. The subject indicates whether a side effect has occurred since the last visit by marking ‘yes’ on the checklist for each of the events listed. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.</description>
          <population>Safety Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervousnes/Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missed Menses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Columbia-Suicide Severity Rating Scale (C-SSRS)</title>
        <description>C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.</description>
        <time_frame>Up to 12 weeks for children aged 6-12 years and up to 15 weeks for adolescents aged 13-17 years</time_frame>
        <population>SP</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Once daily</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine Hydrochloride</title>
            <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
          </group>
          <group group_id="O3">
            <title>Atomoxetine Hydrochloride</title>
            <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
          </group>
        </group_list>
        <measure>
          <title>Columbia-Suicide Severity Rating Scale (C-SSRS)</title>
          <description>C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale. Outcome measure is at 12 weeks for ages 6-12 years and at 15 weeks for ages 13-17 years.</description>
          <population>SP</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal Ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal Behaviour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Once daily</description>
        </group>
        <group group_id="E2">
          <title>Guanfacine Hydrochloride</title>
          <description>Tablet, once daily, optimised dose (1mg to 7mg based on age and weight)</description>
        </group>
        <group group_id="E3">
          <title>Atomoxetine Hydrochloride</title>
          <description>Capsule, once daily, optimised dose (10mg to 100mg based on weight)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="20" subjects_at_risk="111"/>
                <counts group_id="E2" events="29" subjects_affected="19" subjects_at_risk="114"/>
                <counts group_id="E3" events="31" subjects_affected="19" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E2" events="16" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="114"/>
                <counts group_id="E3" events="54" subjects_affected="30" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" events="29" subjects_affected="18" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="111"/>
                <counts group_id="E2" events="45" subjects_affected="29" subjects_at_risk="114"/>
                <counts group_id="E3" events="32" subjects_affected="24" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="23" subjects_affected="12" subjects_at_risk="111"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E3" events="44" subjects_affected="31" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="114"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="114"/>
                <counts group_id="E3" events="24" subjects_affected="17" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="46" subjects_affected="27" subjects_at_risk="111"/>
                <counts group_id="E2" events="51" subjects_affected="30" subjects_at_risk="114"/>
                <counts group_id="E3" events="36" subjects_affected="22" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="111"/>
                <counts group_id="E2" events="94" subjects_affected="50" subjects_at_risk="114"/>
                <counts group_id="E3" events="32" subjects_affected="20" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E2" events="16" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E3" events="18" subjects_affected="7" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="114"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="112"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire Development LLC</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

